Artiva Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics (ARTV) with a Buy rating and $12 price target The company’s primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company’s various Phase 1/2 studies are positive.